Lifeboat Foundation

Research at the Institute of Molecular Biology and Biotechnology (IMBB) of the Foundation for Research and Technology-Hellas (FORTH), published today in the journal Nature Aging, reveals a fundamental quality control mechanism that operates in cells to safeguard the integrity and function of the nucleus. By maintaining nuclear homeostasis, this molecular mechanism contributes critically to promote longevity and fertility.

IMBB researchers Dr. Margarita-Elena Papandreou and Dr. Georgios Konstantinidis, headed by Dr. Nektarios Tavernarakis (Professor at the Medical School, University of Crete, and Chairman of the Board at FORTH), discovered that recycling of nuclear and nucleolar components via autophagy delays aging of somatic cells, and sustains the immortality of germ cells, which are required for reproduction.

The nucleus is the central organelle of all eukaryotic cells that contains the genetic material (DNA), which determines cellular identity and function. During aging and in cancer cells, the ultrastructure of the nucleus is dramatically altered. Moreover, progressive and pronounced deterioration of the nuclear architecture is a common and conserved feature of progeria and numerous other disorders associated with aging.

Although the toxicity of graphene‐based nanomaterials on human health has been extensively studied, their impact on the microbiome remains poorly understood. Using zebrafish as a model, we show that graphene oxide modulates the immune system in a microbiome‐dependent manner through a mechanism mediated by the aryl hydrocarbon receptor. The study suggests an interplay among graphene‐based nanomaterials, microbiome and innate immune system.

For nearly two decades, astrophysicists have believed that long gamma-ray bursts (GRBs) resulted solely from the collapse of massive stars. Now, a new study upends that long-established and long-accepted belief.

Led by Northwestern University.

Established in 1,851, Northwestern University (NU) is a private research university based in Evanston, Illinois, United States. Northwestern is known for its McCormick School of Engineering and Applied Science, Kellogg School of Management, Feinberg School of Medicine, Pritzker School of Law, Bienen School of Music, and Medill School of Journalism.

Scientists have discovered that an inflammatory cytokine known as LIGHT is a major factor in the deadly airway damage that can affect people with severe asthma. This research has suggested that such airway damage could be reversed by therapeutics that halt LIGHT, and the molecule could offer a way to treat asthma. The study, which used a mouse model and human tissue, has been reported in the Journal of Allergy and Clinical Immunology.

“This is a very, very significant finding,” said senior study author and LJI Professor Michael Croft, Ph.D. “This research gives us a better understanding of the potential of therapeutic targeting of LIGHT and what we might do to relieve some of the symptoms and some of the inflammatory features seen in patients who have severe asthma.”

You’d think that existing exclusively within the human body would give way to a complete knowledge of the organs hidden within. Instead, we’re constantly discovering new parts of the weird and glorious biological machine we each call home. The latest in these discoveries are the “tubarial glands,” a pair of small organs responsible for producing saliva.

Scientists at the University of California, San Francisco (UCSF) have engineered molecules that act like “cellular glue,” allowing them to direct in precise fashion how cells bond with each other. The discovery represents a major step toward building tissues and organs, a long-sought goal of regenerative medicine.

Adhesive molecules are found naturally throughout the body, holding its tens of trillions of cells together in highly organized patterns. They form structures, create neuronal circuits, and guide immune cells to their targets. Adhesion also facilitates communication between cells to keep the body functioning as a self-regulating whole.

In a new study, published in the December 12, 2022, issue of Nature, researchers engineered cells containing customized adhesion molecules that bound with specific partner cells in predictable ways to form complex multicellular ensembles.

Lupin Pharmaceuticals issued a voluntary recall of some blood pressure medication due to the potential presence of a nitrosamine impurity, according to a notice published on the Food and Drug Administration’s (FDA) website.

The recall, issued last week, includes one batch of 20-milligram Quinapril Tablets USP — G102929 — and three batches of 40-milligram Quinapril Tablets USP – G100533, G100534 and G203071, the notice said.

Consumers, wholesalers, distributors and retailers can find the lot number on the side of the label affixed to bottles.

Researchers have found a new way to kill cancer cells by using artificial DNA which could pave the way for a cure for the disease in the future. The existing methods of treating cancer have their limitations, however, scientists believe that RNA and DNA-based drugs could potentially help beat the deadly disease.

The findings published in the Journal of the American Chemical Society, last week, show that the researchers at the University of Tokyo have used the chemically synthesised, hairpin-shaped, cancer-killing DNA to target and kill human cervical cancer and breast cancer-derived cells. The DNA pairs were also used against malignant melanoma cells in mice.

The team of researchers at the University of Tokyo, led by Assistant Professor Kunihiko Morihiro and Professor Akimitsu Okamoto from the Graduate School of Engineering, indicated that they were inspired to move away from conventional anti-cancer drug treatments by using artificial DNA.

Immunotherapy is a type of drug that might be an option if you have triple-negative breast cancer.

Triple-negative breast cancer, also called basal-like breast cancer, is not sensitive to hormones. This means that the breast cancer cells don’t use estrogen or progesterone to grow and they don’t have hormone receptors. This type of breast cancer also doesn’t produce too much of the growth-promoting protein called HER2.

“Triple-negative breast cancer is about 10% to 15% of all breast cancer cases,” says Pooja Advani, M.D., a medical oncologist with the Robert and Monica Jacoby Center for Breast Health at Mayo Clinic in Florida.